Back to Cell Types

SHP-77Homo sapiens (Human)Cancer cell line

Also known as: Shadyside Hospital Pittsburgh-77, SHP77

🤖 AI SummaryBased on 9 publications

Quick Overview

Human cancer cell line with potential for drug sensitivity studies.

Detailed Summary

SHP-77 is a human cancer cell line derived from small-cell lung carcinoma (SCLC). It is utilized in research to study drug sensitivity, particularly in relation to Bcl-2 family inhibitors. The cell line has been analyzed for genomic alterations, including copy number gains on chromosome 18q, which are associated with sensitivity to ABT-737, a Bcl-2 inhibitor. These findings suggest that SHP-77 may be a valuable model for investigating the mechanisms of drug response and resistance in SCLC. The cell line's genetic profile, including the amplification of Bcl-2 and NOXA genes, provides insights into the molecular basis of its sensitivity to targeted therapies.

Research Applications

Drug sensitivity studiesGenomic analysis of SCLCBcl-2 family inhibitor research

Key Characteristics

Amplification of Bcl-2 and NOXA genesSensitivity to ABT-737Copy number gains on 18q

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1693
Species	Homo sapiens (Human)
Tissue Source	Lung, left upper lobe[UBERON:UBERON_0008952]

Donor Information

Age	54
Age Category	Adult
Sex	Male
Race	caucasian

Disease Information

Disease	Small cell lung cancer
Lineage	Lung
Subtype	Small Cell Lung Cancer
OncoTree Code	SCLC

DepMap Information

Source Type	ATCC
Source ID	ACH-000790_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Cys176Trp (c.528C>G)	Homozygous	-	Unknown, Unknown
MutationSimple	RAC1	p.Tyr32Cys (c.95A>G)	Heterozygous	-	Unknown, Unknown
MutationSimple	KRAS	p.Gly12Val (c.35G>T)	Heterozygous	Acquired	Unknown, Unknown
MutationSimple	ABL1	p.Val1128Glu (c.3383T>A)	Heterozygous	-	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10,11

D13S317

8

D16S539

11

D18S51

15

D19S433

14,14.1

D2S1338

17,23

D3S1358

17

D5S818

12

D7S820

11

D8S1179

11,13

FGA

19

Penta D

13

Penta E

10

TH01

7

TPOX

9,11

vWA

16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.

Sauter G., Lesniewski R., Semizarov D.

Mol. Cancer Res. 5:331-339(2007).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.

Cole S.P.C., Gerlach J.H.

Clin. Cancer Res. 3:115-122(1997).

Investigation of the genes for RET and its ligand complex, GDNF/GFR alpha-I, in small cell lung carcinoma.

Rabbitts P.H., Sundaresan V., Hofstra R.M.W., Eng C.

Genes Chromosomes Cancer 21:326-332(1998).

Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer.

Lofters W.S., Flynn T.G.

Cancer 75:2442-2451(1995).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

Stability and utility of the unique human small cell carcinoma line SHP-77.

Bahnson A.B., Sherer C.

Cancer Res. 45:2725-2731(1985).

A new in vitro cell line established from human large cell variant of oat cell lung cancer.

Fisher E.R., Paulson J.D.

Cancer Res. 38:3830-3835(1978).

Web Resources

dtp.cancer.gov tcpaportal.org